机构：[1]Molecular Diagnosis Sub Center of Yunnan Cancer Center, Yunnan Cancer Molecular Diagnosis Center, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China[2]Yunnan Provincial Key Laboratory of Panax notoginseng, Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China[3]Cancer Center Office, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China[4]Department of Thoracic Surgery II, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China[5]Department of Medical Affairs, Amoy Diagnostics Co., Ltd., Xiamen, China[6]Imaging Department, Kunming Tongren Hospital, Kunming, China[7]Department of Thoracic Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China
Objective Qujing City, Yunnan Province, China, has a high incidence of lung cancer and related mortality. The etiology of NSCLC in Qujing area and distribution of associated molecular aberrations has not been fully elucidated. This study aimed to reveal the profile of driver gene mutations in patients with non-small-cell lung cancer (NSCLC) in Qujing and explore their relationships with clinicopathological characteristics. Methods In this study, the mutation profiles of NSCLC driver genes, including EGFR, ALK, ROS1, KRAS, BRAF, RET, MET, HER2, NRAS, and PIK3CA, were investigated in patients with NSCLC from Qujing and compared with those from other regions in Yunnan Province. The associations between molecular mutations and clinicopathological characteristics were further analyzed. Results A distinct profile of driver gene mutations was discovered in patients with NSCLC from Qujing. Interestingly, a higher proportion of EGFR compound mutations, including G719X + S768I (19.65% vs 3.38%, P < 0.0001) and G719X + L861Q (21.10% vs 2.82%, P < 0.0001), was observed in patients with NSCLC in Qujing compared with patients in non-Qujing area, besides significantly different distributions of EGFR (46.01% vs. 51.07%, P = 0.0125), ALK (3.17% vs. 6.97%, P = 0.0012), ROS1 (0.5% vs. 2.02%, P = 0.0113), and KRAS (23.02% vs. 7.85%, P < 0.0001). Further, EGFR compound mutations were more likely associated with the occupation of patients (living/working in rural areas, e.g., farmers). Moreover, KRAS G12C was the dominant subtype (51.11% vs 25.00%, P = 0.0275) among patients with NSCLC having KRAS mutations in Qujing. Conclusions Patients with NSCLC in Qujing displayed a unique profile of driver gene mutations, especially a higher prevalence of EGFR compound mutations and dominant KRAS G12C subtype, in this study, indicating a peculiar etiology of NSCLC in Qujing. Therefore, a different paradigm of therapeutic strategy might need to be considered for patients with NSCLC in Qujing.
基金：
National Natural Science FundNational Natural Science Foundation of China (NSFC) [81860513, 81960335]
第一作者机构：[1]Molecular Diagnosis Sub Center of Yunnan Cancer Center, Yunnan Cancer Molecular Diagnosis Center, The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital), Kunming, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou Yongchun,Ge Feng,Du Yaxi,et al.Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.644895.
APA：
Zhou, Yongchun,Ge, Feng,Du, Yaxi,Li, Quan,Cai, Jingjing...&Huang, Yunchao.(2021).Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China.FRONTIERS IN ONCOLOGY,11,
MLA：
Zhou, Yongchun,et al."Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China".FRONTIERS IN ONCOLOGY 11.(2021)
